
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
argenx is poised for success in the biopharmaceutical industry due to its diverse pipeline of innovative antibody-based therapies and the recent FDA approvals for its lead product, Vyvgart. The company's management has shown a strategic focus on targeting rare autoimmune diseases with high unmet medical needs, which has resulted in rapid enrollment and strong demand for its treatments. With potential for multi-billion market opportunities and a promising outlook for its key assets, argenx presents a compelling investment opportunity.
Bears say
argenx is a biotech company with a promising product, Vyvgart, which has gained FDA approval for the treatment of rare autoimmune diseases. However, there are risks involved in the attainment of their price target and rating, including clinical, regulatory, or commercial failure. Although the company has a strong focus on innovation and a promising pipeline, it may take time for these products to generate significant revenue, resulting in a negative outlook from a financial analyst's perspective.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares